146 related articles for article (PubMed ID: 31548719)
1. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.
Alvarez MJ; Yan P; Alpaugh ML; Bowden M; Sicinska E; Zhou CW; Karan C; Realubit RB; Mundi PS; Grunn A; Jäger D; Chabot JA; Fojo AT; Oberstein PE; Hibshoosh H; Milsom JW; Kulke MH; Loda M; Chiosis G; Reidy-Lagunes DL; Califano A
Nat Genet; 2019 Oct; 51(10):1427-1428. PubMed ID: 31548719
[No Abstract] [Full Text] [Related]
2. H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.
Hofving T; Karlsson J; Nilsson O; Nilsson JA
Nat Genet; 2019 Oct; 51(10):1426-1427. PubMed ID: 31548718
[No Abstract] [Full Text] [Related]
3. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
[TBL] [Abstract][Full Text] [Related]
4. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.
Siddique ZL; Drozdov I; Floch J; Gustafsson BI; Stunes K; Pfragner R; Kidd M; Modlin IM
Neuroendocrinology; 2009; 89(4):458-70. PubMed ID: 19295186
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid.
Pfragner R; Behmel A; Höger H; Beham A; Ingolic E; Stelzer I; Svejda B; Moser VA; Obenauf AC; Siegl V; Haas O; Niederle B
Anticancer Res; 2009 Jun; 29(6):1951-61. PubMed ID: 19528452
[TBL] [Abstract][Full Text] [Related]
6. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
7. Morfo-functional nutritional status in patients with gastroenteropancreatic neuroendocrine tumors (GEPNET).
Fernández-Medina B; Vegas-Aguilar I; García-Almeida JM; Sevilla-García I; Hernández-García C; Tinahones-Madueño FJ
Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):466-475. PubMed ID: 35989228
[TBL] [Abstract][Full Text] [Related]
8. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment.
Svejda B; Kidd M; Giovinazzo F; Eltawil K; Gustafsson BI; Pfragner R; Modlin IM
Cancer; 2010 Jun; 116(12):2902-12. PubMed ID: 20564397
[TBL] [Abstract][Full Text] [Related]
9. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
10. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.
Hanazaki K; Sakurai A; Munekage M; Ichikawa K; Namikawa T; Okabayashi T; Imamura M
Surg Today; 2013 Mar; 43(3):229-36. PubMed ID: 23076685
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of novel plant extracts from Trailliaedoxa gracilis (W. W. Smith & Forrest) in human carcinoid KRJ-I Cells.
Svejda B; Aguiriano-Moser V; Sturm S; Höger H; Ingolic E; Siegl V; Stuppner H; Pfragner R
Anticancer Res; 2010 Jan; 30(1):55-64. PubMed ID: 20150617
[TBL] [Abstract][Full Text] [Related]
12. Radiotheranostics in oncology: Making precision medicine possible.
Aboagye EO; Barwick TD; Haberkorn U
CA Cancer J Clin; 2023; 73(3):255-274. PubMed ID: 36622841
[TBL] [Abstract][Full Text] [Related]
13. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Neuroendocrine tumors: the road to precision medicine.
La Salvia A; Giuffrida D; Modica R
Front Endocrinol (Lausanne); 2023; 14():1253319. PubMed ID: 37564989
[No Abstract] [Full Text] [Related]
15. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell lines as patient avatars for drug response prediction.
McDermott U
Nat Genet; 2018 Oct; 50(10):1350-1351. PubMed ID: 30262817
[No Abstract] [Full Text] [Related]
17. Preclinical models for precision oncology.
Ibarrola-Villava M; Cervantes A; Bardelli A
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):239-246. PubMed ID: 29959990
[TBL] [Abstract][Full Text] [Related]
18. Microencapsulation of small intestinal neuroendocrine neoplasm cells for tumor model studies.
Rokstad AM; Gustafsson BI; Espevik T; Bakke I; Pfragner R; Svejda B; Modlin IM; Kidd M
Cancer Sci; 2012 Jul; 103(7):1230-7. PubMed ID: 22435758
[TBL] [Abstract][Full Text] [Related]
19. Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Dec; 4(12):1790. PubMed ID: 30419080
[No Abstract] [Full Text] [Related]
20. Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F; Grass I; Sedding D; Möbs M; Christen F; Benecke J; Fuchs K; Mende S; Kaemmerer D; Sänger J; Kunze A; Geisler C; Freitag H; Lewens F; Worpenberg L; Iwaszkiewicz S; Siegmund B; Walther W; Hummel M; Grabowski P
Neuroendocrinology; 2018; 107(1):1-23. PubMed ID: 28910819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
